<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Dihydrocodeine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01551</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, experimental, illicit</td></tr><tr><th>Description</th><td><p>Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough.</p>
<p>It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01551/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01551/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01551.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01551.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01551.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01551.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01551.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01551">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>DHC</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Dihydrocodeine bitartrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000048/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000048/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: ZGSZBVAEVPSPFM-HYTSPMEMSA-N</li>
              <li>Monoisotopic Mass: 451.184231531</li>
              <li>Average Mass: 451.467</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000048">DBSALT000048</a></td>
      </tr>
      <tr>
        <td>
          <strong>Dihydrocodeine hydrobromide</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000049/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000049/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000049">DBSALT000049</a></td>
      </tr>
      <tr>
        <td>
          <strong>Dihydrocodeine hydrochloride</strong>
          <div class="cas">36418-29-8</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000050/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000050/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: VMZXMTVGOAQUEN-FFHNEAJVSA-N</li>
              <li>Monoisotopic Mass: 337.144471346</li>
              <li>Average Mass: 337.841</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000050">DBSALT000050</a></td>
      </tr>
      <tr>
        <td>
          <strong>Dihydrocodeine hydroiodide</strong>
          <div class="cas">5965-15-1</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000051/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000051/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: QXBJOHDQNJOLNA-PKHFJCIDNA-N</li>
              <li>Monoisotopic Mass: 429.080087059</li>
              <li>Average Mass: 429.2925</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000051">DBSALT000051</a></td>
      </tr>
      <tr>
        <td>
          <strong>Dihydrocodeine methyliodide</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000052/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000052/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000052">DBSALT000052</a></td>
      </tr>
      <tr>
        <td>
          <strong>Dihydrocodeine phosphate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000053/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000053/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: HFBYLYCMISIEMM-FFHNEAJVSA-N</li>
              <li>Monoisotopic Mass: 399.144688703</li>
              <li>Average Mass: 399.3753</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000053">DBSALT000053</a></td>
      </tr>
      <tr>
        <td>
          <strong>Dihydrocodeine sulfate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000054/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000054/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000054">DBSALT000054</a></td>
      </tr>
      <tr>
        <td>
          <strong>Dihydrocodeine tartrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000055/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000055/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000055">DBSALT000055</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Codidol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Contugesic</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dehace</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>DF-118 Forte</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dicogesic</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Hydrocodin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Remedacen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Centussin DHC</td><td>dihydrocodeine bitartrate, brompheniramine maleate, and phenylephrine hydrochloride</td></tr><tr><td>Donatuss DC</td><td>dihydrocodeine bitartrate, phenylephrine hydrochloride, guaifenesin</td></tr><tr><td>J-Max DHC</td><td>dihydrocodeine bitartrate, guaifenesin</td></tr><tr><td>Panlor DC</td><td>acetaminophen + caffeine + dihydrocodeine</td></tr><tr><td>POLY HIST DHC</td><td>dihydrocodeine bitartrate, phenylephrine hydrochloride, pyrilamine maleate</td></tr><tr><td>Poly-Tussen Ex</td><td>dihydrocodeine bitartrate, phenylephrine hydrochloride, guaifenesin</td></tr><tr><td>Synalgos</td><td>Caffeine + Acetylsalicylic acid + Dihydrocodeine</td></tr><tr><td>Synalogos</td><td>acetylsalicylic acid, caffeine, dihydrocodeine bitartrate,</td></tr><tr><td>Trezix</td><td>acetaminophen, caffeine, dihydrocodeine bitartrate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/analgesics-opioid">Analgesics, Opioid</a></li></ul></td></tr><tr><th>CAS number</th><td>125-28-0</td></tr><tr><th>Weight</th><td>Average: 301.3801<br>Monoisotopic: 301.167793607</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>23</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>RBOXVHNMENFORY-DNJOTXNNSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC[C@@H]2O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Morphinans</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Morphinans</td></tr><tr><th>Alternative parents</th><td>Benzylisoquinolines; Phenanthrenes and Derivatives; Tetralins; Benzofurans; Anisoles; Cyclohexanols; Alkyl Aryl Ethers; Piperidines; Cyclic Alcohols and Derivatives; Tertiary Amines; Polyamines</td></tr><tr><th>Substituents</th><td>phenanthrene; tetralin; benzofuran; phenol ether; anisole; cyclohexanol; alkyl aryl ether; benzene; piperidine; cyclic alcohol; tertiary amine; secondary alcohol; polyamine; ether; alcohol; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Dihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain [2]. It  can also be used to treat chronic pain [1], breathlessness and coughing. 

In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014322/]
 </td></tr><tr><th>Pharmacodynamics</th><td>Possible opioid related side effects include, but are not limited to, drowsiness, nausea, headache, dry mouth, constipation, difficulty passing urine, and mild euphoria. </td></tr><tr><th>Mechanism of action</th><td>Dihydrocodeine is metabolized to dihydromorphine -- a highly active metabolite with a high affinity for mu opioid receptors. [3]</td></tr><tr><th>Absorption</th><td>Bioavailability is low (approximately 20%) if administered orally. This may be due to poor gastrointestinal absorption. It is also likely due to pre-systemic metabolism by the liver and intestinal wall. [2] 

The AUCs after oral and intravenous administration are similar (3203ug/l/h and 3401ug/l/h, respectively). [2]


Time to peak values are 1.6 and 1.8hours for a 30mg and 60mg dose, respectively. The concentrations achieved were 71.8 ug/1 and 146 ug/1, respectively. [2]</td></tr><tr><th>Volume of distribution</th><td><p>The disposition of dihydrocodeine is described as a two compartment model. <sup class="footnote" id="fnr2"><a href="#fn2">2</a></sup></p></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolized in the liver by CYP 2D6 into an active metabolite, dihydromorphine, and by CYP 3A4 into secondary primary metabolite, nordihydrocodeine. A third primary metabolite is dihydrocodeine-6-glucuronide. [1] 

The time for mean peak concentration in acid metabolites is 1.76h and 1.98h for a 30 and 60mg dose, respectively. The concentrations achieved were 563 ug/1 and 1476 ug/1, respectively. [2]

</p></td></tr><tr><th>Route of elimination</th><td>Renal elimination and urinary excretion. [1]</td></tr><tr><th>Half life</th><td>4h</td></tr><tr><th>Clearance</th><td><p>Plasma clearance is approximately 300ml/min. <sup class="footnote" id="fnr2"><a href="#fn2">2</a></sup></p>
<p>The pharmacokinetics of dihydrocodeine and active metabolite dihydromorphine have been reported to be linear. <sup class="footnote" id="fnr1"><a href="#fn1">1</a></sup></p>
<p>The decline in plasma dihydrocodeine concentrations after intravenous administration has been described as bi-exponential, with a sleep decline in the initial 2h following administration, followed by a mono-exponential decline thereafter. Clearance was not dose dependent. <sup class="footnote" id="fnr2"><a href="#fn2">2</a></sup></p></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9942</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9974</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8388</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8754</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5937</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9652</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5676</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.831</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.9143</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7941</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8554</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9074</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.7395</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7689</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8114</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.957</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8074
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9522
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9857
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9382 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9058
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8246
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bocapharmacal.com">Boca Pharmacal</a></li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li>Leitner Pharmaceuticals LLC</li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pamlab.com">Pamlab LLC</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li>
<li><a href="http://www.zerxis.com">Zerxis Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Elixir</td><td>Oral</td><td></td></tr><tr><td>Injection</td><td>Intramuscular</td><td></td></tr><tr><td>Injection</td><td>Intramuscular</td><td>50MG/ML</td></tr><tr><td>Injection</td><td>Subcutaneous</td><td></td></tr><tr><td>Solution</td><td>Oral</td><td></td></tr><tr><td>Suppository</td><td>Rectal</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td>30MG</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>120MG</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>60MG</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>112.5 &#176;C</td><td>PhysProp</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>2.38e+00 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.58</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.55</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2.1</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>14.15</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>9.33</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>41.93</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>83.64</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>32.82</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Igor Likhotvorik, &#8220;Preparation of dihydrocodeine from codeine.&#8221; U.S. Patent US06887999, issued May 03, 2005.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=06887999&amp;tbm=pts" target="_blank">US06887999 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><p>1. Ammon, Susanne, et al. &#8220;Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing.&#8221; British journal of clinical pharmacology 48.3 (1999): 317-322.</p>
<p>2. Rowell, F. J., R. A. Seymour, and M. D. Rawlins. &#8220;Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites.&#8221; European journal of clinical pharmacology 25.3 (1983): 419-424.</p>
<p>3. Schmidt, H., et al. &#8220;The role of active metabolites in dihydrocodeine effects.&#8221; International journal of clinical pharmacology and therapeutics 41.3 (2003): 95-106.</p></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D01481" target="_blank">D01481 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C08024" target="_blank">C08024 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5284543" target="_blank">5284543 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506478" target="_blank">46506478 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.4447600.html" target="_blank">4447600 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449322" target="_blank">PA449322 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/international/dihydrocodeine.html" target="_blank">http://www.drugs.com/international/dihydrocodeine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Dihydrocodeine" target="_blank">Dihydrocodeine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Opioids may enhance Alvimopan toxicity, especially when opiate use for more than 7 days is in place prior to alvimopan initiation. Alvimopan is contraindicated for use if patients have been dosed with opioids for more than 7 consecutive days. </td></tr><tr><td><a href="/drugs/DB06767">Ammonium chloride</a></td><td>May enhance excretion of dihydrocodeine. Recommended to monitor for reduced therapeutic effect. </td></tr><tr><td><a href="/drugs/DB00182">Amphetamine</a></td><td>Amphetamines may enhance analgesic effects of dihydrocodeine. Monitor for enhanced analgesia. Dose reductions of dihydrocodeine may be appropriate. </td></tr><tr><td><a href="/drugs/DB00972">Azelastine</a></td><td>Enhanced CNS depressant effects contraindicates concurrent use. </td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Phenothiazines may enhance hypotensive effects of opioid analgesics. It is recommended to monitor patients for hypotension.  </td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>CNS depressants may enhance the adverse effects and toxicity of other CNS depressants. It is recommended to monitor therapy. </td></tr><tr><td><a href="/drugs/DB00035">Desmopressin</a></td><td>Opioids may enhance the adverse effects and toxicity of desmopressin. It is recommended to monitor therapy. </td></tr><tr><td><a href="/drugs/DB00450">Droperidol</a></td><td>Enhanced CNS depressant effects are possible. Consider dose reduction of a CNS agent, if concurrent use is not avoidable.  </td></tr><tr><td><a href="/drugs/DB00999">Hydrochlorothiazide</a></td><td>Dihydrocodeine may enhance the hypotensive effects of thiazide diuretics. 
It is recommended to monitor therapy.</td></tr><tr><td><a href="/drugs/DB00557">Hydroxyzine</a></td><td>May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy. </td></tr><tr><td><a href="/drugs/DB00653">Magnesium Sulfate</a></td><td>May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy. </td></tr><tr><td><a href="/drugs/DB00765">Metyrosine</a></td><td>Concurrent use may enhance the sedative effect of Metyrosine.  It is recommended to monitor therapy. </td></tr><tr><td><a href="/drugs/DB00104">Octreotide</a></td><td>Concurrent use may enhance the analgesic effect of dihydrocodeine. It is recommended to monitor therapy, and reduce the dose of dihydrocodeine as appropriate.  </td></tr><tr><td><a href="/drugs/DB00038">Oprelvekin</a></td><td>May increase the serum levels of opioid analgesics. It is recommended to monitor therapy for the signs and symptoms of respiratory depression and enhanced sedation. </td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Opioid analgesics may enhance the 5HT effects of SSRIs to cause serotonin syndrome. It is recommended to monitor therapy.</td></tr><tr><td><a href="/drugs/DB00082">Pegvisomant</a></td><td>Opioids may diminish the therapeutic effect of pegvisomant. It is recommended to monitor therapy. </td></tr><tr><td><a href="/drugs/DB08883">Perampanel</a></td><td>Enhanced CNS depressant effects. Consider therapy modification, and avoid performing complex and high risk activities like driving until side effects are known. </td></tr><tr><td><a href="/drugs/DB00413">Pramipexole</a></td><td>Dihydrocodeine may enhance the sedative effect of pramipexole. It is recommended to monitor therapy</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Use of quinidine may reduce dihydrocodeine's analgesic effect.  </td></tr><tr><td><a href="/drugs/DB00268">Ropinirole</a></td><td>Dihydrocodeine may enhance the sedative effect of ropinirole. It is recommended to monitor therapy</td></tr><tr><td><a href="/drugs/DB05271">Rotigotine</a></td><td>Dihydrocodeine may enhance the sedative effect of rotigotine. It is recommended to monitor therapy.</td></tr><tr><td><a href="/drugs/DB00202">Succinylcholine</a></td><td>May enhance the bradycardic effect of opioid analgesics. It is recommended to monitor therapy. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Dihydrocodeine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00425">Zolpidem</a></td><td>Enhanced CNS depressant effects contraindicates concurrent use for certain brand name formulations of zolpidem. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Alcohol may enhance CNS depressant effects</li></ul></td></tr></tbody></table>